Source: NuGen.
  • Common shares of NuGen Medical Devices (NGMD) have begun trading on the OTCQB under the symbol NGMDF
  • The company’s common shares will continue to trade on the TSX Venture Exchange under the symbol NGMD
  • Trading on the OTCQB will provide NuGen with added visibility to U.S. investors
  • The company also reports that it is awaiting approval for its application for DTC eligibility
  • NuGen is a specialty medical device company
  • NuGen Medical Devices (NGMD) is up 9.52 per cent on the day, trading at C$0.115 per share at 1:30 pm ET

Common shares of NuGen Medical Devices (NGMD) have begun trading on the OTCQB under the symbol NGMDF.

The company’s common shares will continue to trade on the TSX Venture Exchange under the symbol NGMD.

“Commencing trading on the OTCQB venture exchange is an important milestone for NuGen,” stated Michael Wright, CEO of NuGen.

“Having our common shares available on the OTCQB will increase accessibility for American investors interested in directly participating in NuGen’s growth with the same ease as their Canadian counterparts.”

The OTCQB Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their financial reporting and undergo an annual verification and management certification process.

The company also reports that it is awaiting approval for its application for DTC eligibility for electronic settlement and transfer of its common shares in the United States.

NuGen is a specialty medical device company developing needle-free technologies and other innovative medical delivery products.

NuGen Medical Devices (NGMD) is up 9.52 per cent on the day, trading at C$0.115 per share at 1:30 pm ET.


More From The Market Online

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Oncolytics Biotech approved to expand pancreatic cancer program

Oncolytics Biotech (TSX:ONC), a cancer immunotherapy stock, receives ethics and German regulatory approvals for a new pancreatic cancer study.